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Objective: Mutation rate in domain of EGFR gene varies between 
populations of lung cancer patients. Primary aim of this study was 
to analyze clinical and pathological characteristics, and tumor, node, 
metastasis status and stage of diseases, in relation to mutation status.
Methods: After histological confirmation of lung adenocarcinoma 
tissue obtained during bronchoscopy was consecutively sent for 
EGFR testing. Genomic DNA extraction was performed with the 
QIAamp DNA FFPE Tissue kit. Clinical data for multivariate analy-
sis were extracted from hospital based-lung cancer registry.
Results: Among 360 tested patients, there was 67.8% males and 32.2% 
females, aged 61 ± 9.8 years. Majority of patients were smokers (57.0%) 
with Eastern Cooperative Oncology Group 1 performance status 
(92.2%). Mutation in EGFR gene was detected in 42 (11.7%) patients. 
Deletion in exon 19 was detected in 24 (6.7%) patients, mutation in 
exon 21 in 17 (4.7%), and mutation in exon 18 in one patient (0.3%). 
Patients were mostly diagnosed in stage IV adenocarcinoma (74.4%). 
Statistically significant differences were determined in relation to smok-
ing (p < 0.001), T descriptor (size; p = 0.019) and gender (p = 0.002).
Conclusions: Mutation rate in domain of EGFR gene in investigated 
lung cancer population is in range with reported data in Caucasian 
race. Smoking, T descriptor and gender were found to be related to 
the EGFR status.
Key Words: Adenocarcinoma of the lung, Epidermal growth factor recep-
tor, lung cancer, Mutation, non–small-cell lung cancer, targeted therapy
(J Thorac Oncol. 2014;9: 1406–1410)
Testing of tumor tissue for presence of activating mutations in domain of EGFR gene became routine in the diagnostic 
algorithm for evaluation of lung adenocarcinoma.1–5 General 
recommendations of expert societies state that clinical charac-
teristics (such as gender, age, ethnicity, and smoking history) 
are not sufficiently sensitive to select patients for molecu-
lar testing. However, it is well known that mutation rate in 
domain of the EGFR gene in adenocarcinoma of the lung is 
higher in Asian population, women, and non-smokers.6–12 In a 
limited resource setting, especially in low-income countries, 
molecular tests are not readily available to test all patients. In 
that case, some kind of clinical or clinicopathological selec-
tion must be imposed. Major aims of this study were determi-
nation of mutation rate in domain of EGFR gene in patients 
with adenocarcinoma of the lung among Caucasian Serbian 
population, and evaluation of relationship between clinical 
characteristics and tumor, node, metastasis (TNM) status on 
one side and mutation rate on the other.
In a situation when EGFR mutation testing rate drops 
significantly, mainly because of discontinuation of support 
from pharmaceutical industry, it is essential to know how 
many patients absolutely need to be tested to receive the most 
appropriate treatment. Knowing the EGFR mutation rate in 
lung adenocarcinoma population and its relation with clinical 
characteristics and TNM staging might facilitate creation of 
appropriate national strategy to implement molecular testing 
in routine medical oncology diagnostics.
METHODS
The study was a prospective, non-randomized trial, con-
ducted at the Institute for Pulmonary Diseases of Vojvodina 
and the Institute for Oncology and Radiology of Serbia in the 
period from January 2012 to November 2013. It was approved 
by the institutional review and ethics board. All of the patients 
screened for the enrollment were previously scheduled for 
routine bronchoscopy, because of high suspicion of having 
lung cancer established according to imaging studies. After 
bronchoscopy and confirmation of lung adenocarcinoma 
histology, all tumor tissue samples with adequate histology 
were consecutively sent to pathology department and genetic 
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laboratory for EGFR mutation status testing. Inclusion criteria 
were: age over 18 years; histological or cytological confirma-
tion of lung adenocarcinoma; chemotherapy, targeted ther-
apy, and radiotherapy naïve; stage IIIB or IV; and sufficient 
amount of tissue for genetic testing. Exclusion criteria were 
non-adenocarcinoma of the lung histology/cytology, previous 
chemotherapy, radiotherapy or targeted therapy, and insuffi-
cient amount of tissue.
Genomic DNA used for EGFR mutation analysis was iso-
lated from formalin-fixed and paraffin-embedded tumor samples 
from 360 patients with non–small-cell lung cancer. Genomic 
DNA extraction was performed with the QIAamp DNA FFPE 
Tissue kit (QIAGEN, United Kindgom). For determining the 
28 different mutations in exons 18–21 of the EGFR gene, ther-
ascreen EGFR PCR Kit (QIAGEN Manchester Ltd., United 
Kingdom) was used. All statistical analyses were performed 
with SPSS for Windows version 15.0 (SPSS Inc., Chicago, IL).
RESULTS
There was 244 (67.8%) male and 116 (32.2%) female 
patients, average age 61 ± 9.8, range from 38 to 78, enrolled 
in this trial. Majority of patients, 332 (92.2%) were Eastern 
Cooperative Oncology Group performance status 1. Most 
of patients were active and former smokers 204 (57.0%) 
and 77 (21.5%), respectively. Demographic characteristics 
are given in Table 1. Among 360 evaluated lung adenocar-
cinoma patients, 42 (11.7%) are harboring EGFR mutation. 
Twenty four patients or 6.7% have deletion in exon 19, and 
17 (4.7%) have mutation in exon 21, whereas one patient 
(0.3%) has mutation in exon 18. Two-hundred sixty-eight 
patients or 74.4% were diagnosed in stage IV, whereas 92 
(25.6%) patients were in stage IIIB. Characteristics related to 
clinical staging are given in Table 2. Considering the fact that 
74.2% of patients were diagnosed with metastatic (M1) dis-
ease, evaluation of subgroup with metastases was performed. 
Subgroup analysis was performed in relation to the site of the 
metastasis. Most often metastatic spread involved contralat-
eral lung, pleural effusion, adrenal glands, brain, bones, and 
liver. Cough was the most common symptom in the investi-
gated group, present in 242 (67.2%) of patients. Multivariate 
analysis evaluated all demographic data, clinical characteris-
tics, symptoms and signs, and site of metastases.
Statistically significant relation was found between pos-
itive EGFR mutation status and gender (p = 0.002), T status 
in TNM classification (p = 0.019), and smoking (p < 0.001). 
Results of multivariate analysis along with p values are given 
in Table 3.
DISCUSSION
One of the most important results of this trial is insight 
into mutation status of the EGFR gene in lung adenocarci-
noma of Eastern European Caucasian population. Mutation 
rate in domain of EGFR gene is highly dependent on race, 
being highest in Eastern Asia population and lowest in Nordic 
European countries. Serbian population is relatively homoge-
neous because migrations bypassed Eastern Europe because 
of poor income of the countries. Finally, these results fill in the 
gap in reports from various geographical regions.
EGFR mutation rate varies between populations of 
patients with lung adenocarcinoma and ranges from 10% 
to 15% in Caucasian population to over 50% in most Asian 
populations. Average mutation rate detected in our study 
is 11.7%, what correlates with the average for Caucasian 
race. Only data originating from Slavic ethnicity came from 
a Russian trial1 which reported high mutation rate of 20%. 
In the most recently published French trial,2 EGFR muta-
tion rate detected after testing of 1332 patients was 13.5% 
with slight predominance of exon 19 deletion (52.7%) over 
L858R mutation detected in 48.3% of patients. The same 
TABLE 1.  Demographic Characteristics
Characteristic N (%)
Gender
 Male 244(67.8)
 Female 116 (32.2)
Smoking history
 Active smoker 204 (57.0)
 Former smoker 77 (21.5)
 Non-smoker 77 (21.5)
EGFR status
 Wild type 318 (88.3)
 Mutated 42 (11.7)
Type of mutation in 21 mutated patients
 Exon 19 deletion 24 (6.7)
 Exon 21 mutation 17 (4.7)
 Exon 18 mutation 1 (0.3)
TABLE 2.  Characteristics Related to Clinical Staging in 
Patients Tested for EGFR Mutation
Characteristic N (%)
T factor (TNM)
 T1a 12(3.3)
 T1b 9 (2.5)
 T2a 51 (14.2)
 T2b 29 (8.1)
 T3 101 (28.1)
 T4 158 (43.9)
N factor (TNM)
 N0 66 (18.3)
 N1 10 (2.8)
 N2 127 (35.3)
 N3 157 (43.6)
M factor (TNM)
 M0 93 (25.8)
 M1a 137 (38.1)
 M1b 130 (36.1)
Stage
 IIIB 92 (25.6)
 IV 268 (74.4)
TNM, tumor, node, metastasis classification.
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pattern is observed in our trial. Millela et al.3 investigated 
EGFR molecular profiling in a phase II study in molecularly 
or clinically selected patients pretreated with chemotherapy. 
Comparable age was observed in our group and this Italian 
trial. Gender distribution in Milella’s study revealed 59.6% 
of male and 40.4% of female patients, also comparable with 
the one observed in our group (67.8% male versus 32.2% 
female). EGFR mutation rate was detected in 9% of patients 
evaluated in this study, whereas we observed it in 11.7% of 
Serbian lung adenocarcinoma population. One of the corner-
stone trials defining relations between clinicopathological 
characteristics and EGFR mutation status was published in 
2006 by US group of authors led by Tsao et al.4 In a general 
population of tested lung cancer patients with mixed ethnicity 
mutation rate was 8.8%, lower that observed in our cohort. 
One of the Norwegian studies5 recently reported about EGFR 
mutation rate in unselected group of lung cancer patients of 
Nordic origin. The EGFR mutation rate in Helland’s trial13 
was 7.5% with predominance of exon 19 deletion and exon 
21 point mutation. Authors did not find significant associa-
tion between the type of mutation and clinicopathological 
characteristics. In one of the most recent studies from India,6 
EGFR mutation rate in Indian lung adenocarcinoma patients 
was higher than reported in Caucasian race but lower than in 
Asian. EGFR mutation rate in India was detected in 25.9% 
of patients with adenocarcinoma of the lung. In that study 
exon 19 deletion was correlated with gender, never smok-
ers, pleural effusion and distant metastases (p < 0.05). We 
also observed relation of EGFR mutation rate with smok-
ing, but we did not find correlation between mutation rate 
and distant metastases (p = 0.793) or pleural effusion (p = 
0.304). Frequency of exon 19 deletion in Indian trial was 
51.2% in our study 66.6%, whereas point mutation in exon 
21 was observed in 34.9% of Indian patients and 33.3% of 
Serbian patients. Sahoo et al.7 reported slightly higher EGFR 
mutation rate in Indian patients than previous trial. Exon 19 
deletion was detected in 52% of EGFR-mutated lung adeno-
carcinoma patients, whereas exon 21 mutation was present 
in 26% of the cases. Several Chinese studies reported simi-
lar results about EGFR mutation rate and clinicopathological 
characteristics in lung adenocarcinoma.8–10 In these Chinese 
studies, mutation rate in the domain of EGFR gene in ade-
nocarcinoma of the lung ranges from 37% to 66%. This is 
significantly higher than the rate observed in our group. The 
North African results were recently published by Moroccan 
group.11 The overall frequency of EGFR mutation was 21%, 
with mainly exon 19 deletion (69%) and point mutation in 
exon 21 and 20 in 28%. Higher mutation rate than Western 
European but lower than Asian. Most comprehensive study 
on frequency of EGFR mutation in African American popu-
lation of patients with lung adenocarcinoma was published 
by Reinersman.12 Overall mutation rate in African American 
population was found to be 19%, with 78% of exon 19 
deletions, and 22% of exon 21 point mutations. In Korean 
population, EGFR mutation rate among patients with adeno-
carcinoma of the lung was 51.3% in most recently published 
study.14 This is one of the trials in which exon 19 deletion 
is not the most frequent type of mutation in EGFR domain. 
Majority of Japanese studies report higher mutation rate in 
the domain of the EGFR gene in adenocarcinoma of the lung 
when compared with Caucasian studies. The EGFR mutation 
rate in Japanese adenocarcinoma population ranges between 
20% and 40%.13,15
CONCLUSIONS
Knowing the frequency of EGFR mutation in various 
geographical regions might be of importance to evaluate 
global lung cancer burden and build national and international 
strategies for overcoming this disease especially through tar-
geted therapy treatment. It is obvious that the lowest mutation 
rate is observed in Western European countries, that mutation 
rate rises over North Africa, Russia, and India and peaks in Far 
TABLE 3.  Results of Multivariate Analysis Along With  
p Values
Multivariate Analysis
Demographic Characteristic p Value
Gender p = 0.002*
Age p = 0.243
 Smoking history p < 0.001*
 Pack-years index p = 0.019*
 Tumor size p = 0.247
 ECOG p = 0.217
Clinical characteristic
 T factor (TNM) p = 0.019*
 N factor (TNM) p = 0.863
 M factor (TNM) p = 0.793
 Stage p = 0.783
Site of metastasis
 Pleural nodes p = 0.756
 Pericardial effusion p = 0.915
 Pleural effusion p = 0.304
 Contralateral pulmonary 
node(s)
p = 0.904
 Brain p = 0.363
 Liver p = 0.373
 Adrenal gland p = 0.178
 Bones p = 0.629
 Other p = 0.811
Symptoms and signs
 Cough p = 0.435
 Dyspnea p = 0.761
 Chest pain p = 0.521
 Hemoptysis p = 0.857
 Hoarseness p = 0.562
 Dysphagia p = 0.700
 Body weight loss p = 0.394
 Fever p = 0.418
 Neurological disorders p = 0.404
 Bone pain p = 0.915
TNM, tumor, node, metastasis classification; ECOG, Eastern Cooperative Oncology 
Group.
*Statistically signifcant.
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East Asia (Fig. 1). There are no sufficient data on frequency of 
EGFR mutation in lung adenocarcinoma patients from Middle 
East, Eastern Europe, North and South Africa, Persian area, 
Central Asia, or South America. In Serbian population, we 
observed similar mutation rate as in Western Europe.
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